Mobile, AL, United States of America

Srikanth Kakamanu

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Forwardvue Pharma, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Srikanth Kakamanu. Retrieved from https://idiyas.com/inventor/srikanth-kakamanu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Srikanth Kakamanu and His Work on CAI Nanoemulsions.

Introduction

Srikanth Kakamanu is an inventor associated with Mobile, Alabama, and Forwardvue Pharma, Inc. His patent work concerns a formulation of carboxy-amido-triazole, or CAI, for potential use in treating inflammatory optic neuropathies.

Latest Patents

Kakamanu is associated with 1 patent, titled “CAI Nanoemulsions.” The disclosure describes nanoemulsions containing 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide, methods for preparing them, and their use in treating inflammatory optic neuropathies.

Career Highlights

His listed work connects pharmaceutical formulation research with the development of nanoemulsion delivery approaches. The patent disclosure focuses on preparing CAI in a formulation intended for therapeutic applications.

Collaborations

Kakamanu’s listed coworkers include Alan J. Franklin and Laurent Balenci. Their names are associated with the professional and patent context provided for his work at Forwardvue Pharma, Inc.

Conclusion

Srikanth Kakamanu’s patent activity centers on CAI nanoemulsions and their potential application in treating inflammatory optic neuropathies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…